Skip to main content

Table 2 Risk of common adverse events for discrete time periods following initiation of therapy

From: Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

Time interval

Treatment arm

Adverse event

  

Cough

Diarrhoea

Vomiting

  

Risk*

HR† (95% CI)

p-value

Risk*

HR† (95% CI)

p-value

Risk*

HR† (95% CI)

p-value

1-3 days

AL

7.8%

1.14 (0.71-1.84)

0.59

4.1%

1.13 (0.59-2.19)

0.71

1.2%

1.36 (0.41-4.44)

0.61

 

DP

8.9%

  

4.7%

  

1.7%

  

4-28 days

AL

39.8%

1.17 (0.93-1.48)

0.18

18.5%

0.81 (0.57-1.15)

0.23

2.1%

2.10 (0.92-4.79)

0.08

 

DP

47.1%

  

15.1%

  

4.4%

  

28-63 days

AL

51.9%

0.99 (0.68-1.46)

0.97

22.1%

0.90 (0.53-1.53)

0.70

11.6%

0.70 (0.34-1.43)

0.33

 

DP

47.1%

  

18.9%

  

7.4%

  
  1. * Cumulative risk during time interval of interest estimated using the Kaplan-Meier product limit formula
  2. † HR = hazard ratio for DP vs. AL, generated using multivariate Cox proportional hazard models adjusted for repeated measures in the same patient
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us